# A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

> **NCT03285308** · PHASE3 · TERMINATED · sponsor: **Allergan** · enrollment: 336 (actual)

## Conditions studied

- Gastroparesis
- Diabetes Mellitus

## Interventions

- **DRUG:** Placebo
- **DRUG:** Relamorelin

## Key facts

- **NCT ID:** NCT03285308
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-29
- **Primary completion:** 2020-07-08
- **Final completion:** 2020-07-08
- **Target enrollment:** 336 (ACTUAL)
- **Why stopped:** The Relamorelin program is being terminated solely based on a business decision.
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03285308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03285308, "A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03285308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*